Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Norwegian University of Science and Technology | OTHER |
Not provided
Not provided
Not provided
Not provided
The purpose of the study is to determine the effect of aerobic interval training in patients with an implantable cardioverter defibrillator (ICD) on physical fitness, quality of life and the amount of serious ventricular arrhythmic events on short and long term.
In this study, participants will be randomly assigned to either take part in the exercise program or serve as control and live as usual. At baseline study visit, study researchers will review medical records to collect various information, including the reason for needing an ICD, the type and settings of the ICD, medication use and medical history etc. All participants will undergo blood collection, complete a questionnaire to assess quality of life and undergo examination with echocardiography and ECG. The ICD will be programmed accordingly to international guidelines regarding ICD-therapy and optimal monitoring, before each participant complete an exercise treadmill test to determine VO2 peak. They will wear a Holter monitor to record heart activity 48 hours before the test and 24 hours after the test. All participants will then be observed for 2 months before being randomly assigned to either intervention or control. During this observation period, they will wear a fitness activity tracker wristband to evaluate degree of physical activity and a Holter monitor to register number of premature ventricular contractions. Participants taking part in the interval training group will perform aerobic interval training 4 x 4 minutes intervals, 3 times a week for 12 weeks (week 1-12), whereas participants taking part in the control group will carry on with usual daily life with no lifestyle recommendations. All participants will then undergo a new period of observation (week 13-20) and repeat the tests and examinations performed at baseline and during the observation period prior to intervention/control.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Interval training group | Experimental | Aerobic interval training during 12 weeks 3 times a week. |
|
| Control group | No Intervention | No lifestyle recommendations. Usual daily life. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Interval exercise | Behavioral | Aerobic interval training during 12 weeks 3 times a week: 4 x 4 minutes intervals at an intensity of 90-95% of VO2 peak and active breaks of 3 minutes between intervals. |
| Measure | Description | Time Frame |
|---|---|---|
| Change in physical fitness/aerobic capacity | Expressed in and measured with maximal oxygen uptake (VO2 peak) | Change from baseline and after ended intervention period (12 weeks) |
| Change in assessment of quality of life | Patient-reported survey of patient health SF-36 | Change from baseline and after intervention period (12 weeks) |
| Measure | Description | Time Frame |
|---|---|---|
| Change in burden of ventricular arrhythmias from baseline to week 9-12 | Evaluated by number of ICD discharges (registered on ICD) | Baseline and the last 4 weeks of intervention period (week 9-12) |
| Change in burden of ventricular arrhythmias from baseline to week 13-16 |
Not provided
Inclusion Criteria:
In case of difficulties with patient inclusion for the study, the criteria might be broadened to include patients with idiopathic ventricular arrhythmia as cause for implantation.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Rune Wiseth, MD, Prof | St. Olavs Hospital | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| St Olavs Hospital | Trondheim | Norway |
Individual participant data for all primary and secondary outcome measures will be made available after deidentification and publication
Not provided
After publication
Not yet decided
Not provided
Not provided
| ID | Term |
|---|---|
| D017180 | Tachycardia, Ventricular |
| ID | Term |
|---|---|
| D013610 | Tachycardia |
| D001145 | Arrhythmias, Cardiac |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000072696 | High-Intensity Interval Training |
| ID | Term |
|---|---|
| D064797 | Physical Conditioning, Human |
| D015444 | Exercise |
| D009043 | Motor Activity |
| D009068 | Movement |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
Evaluated by number of ICD discharges (registered on ICD) |
| Baseline and the first 4 weeks after intervention period (week 13-16) |
| Change in burden of ventricular arrhythmias from baseline to week 9-16 | Evaluated by number of ICD discharges (registered on ICD) | Baseline and the last 4 weeks of intervention period plus 4 first weeks after intervention period (week 9-16) |
| Change in burden of ventricular arrhythmias from baseline to week 9-12 | Evaluated by number of episodes with antitachycardia pacing (registered on ICD) | Baseline and the last 4 weeks of intervention period (week 9-12) |
| Change in burden of ventricular arrhythmias from baseline to week 13-16 | Evaluated by number of episodes with antitachycardia pacing (registered on ICD) | Baseline and the first 4 weeks after intervention period (week 13-16) |
| Change in burden of ventricular arrhythmias from baseline to week 9-16 | Evaluated by number of episodes with antitachycardia pacing (registered on ICD) | Baseline and the last 4 weeks of intervention period plus 4 first weeks after intervention period (week 9-16) |
| Change in burden of ventricular arrhythmias from baseline to week 9-12 | Evaluated by number of episodes with monitored ventricular tachycardias without ICD-therapy (registered on ICD) | Baseline and the last 4 weeks of intervention period (week 9-12) |
| Change in burden of ventricular arrhythmias from baseline to week 13-16 | Evaluated by number of episodes with monitored ventricular tachycardias without ICD-therapy (registered on ICD) | Baseline and the first 4 weeks after intervention period (week 13-16) |
| Change in burden of ventricular arrhythmias from baseline to week 9-16 | Evaluated by number of episodes with monitored ventricular tachycardias without ICD-therapy (registered on ICD) | Baseline and the last 4 weeks of intervention period plus 4 first weeks after intervention period (week 9-16) |
| Change in burden of ventricular arrhythmias from baseline to week 9-12 | Evaluated by number of premature ventricular contractions (registered on a 72 hours Holter monitoring) | Baseline and the last 4 weeks of intervention period (week 9-12) |
| Change in burden of ventricular arrhythmias from baseline to week 13-16 | Evaluated by number of premature ventricular contractions (registered on a 72 hours Holter monitoring) | Baseline and the first 4 weeks after intervention period (week 13-16) |
| Change in burden of ventricular arrhythmias from baseline to week 9-16 | Evaluated by number of premature ventricular contractions (registered on a 72 hours Holter monitoring) | Baseline and the last 4 weeks of intervention period plus 4 first weeks after intervention period (week 9-16) |
| Cardiac function | Evaluated by changes in left ventricular dimensions and systolic/diastolic function assessed by echocardiography and blood values (NT-proBNP and troponin T) | Baseline and after ended intervention period (12 weeks) |
| Change in degree of physical activity | Assessed by number of steps daily registered with fitness activity tracker wristband (worn for 1 week) | Baseline and after ended intervention period (12 weeks) |
| Changes in adiposity | Evaluated by changes in waist circumference (cm) and BMI (kg/m^2) as measures of adiposity | Baseline and after ended intervention period (12 weeks) |
| Changes in cholesterol value | Evaluated by changes in total cholesterol, HDL-cholesterol, LDL-cholesterol (all in mmol/L) as a measure of cardiac risk | Baseline and after ended intervention period (12 weeks) |
| Changes in triglycerides value | Evaluated by changes in triglycerides ( in mmol/L) as a measure of cardiac risk | Baseline and after ended intervention period (12 weeks) |
| Changes in heart rate variability | Evaluated by measuring changes in SDNN, SDANN 5, ASDNN 5 and RMSSD registered on a 72 hours Holter monitoring | Baseline and after ended intervention period (12 weeks) |
| Changes in number of premature ventricular contractions during a single bout of high intensity exercise (VO2 peak test) | Measured by changes in the number of premature ventricular contractions during VO2 peak testing | Baseline and after ended intervention period (12 weeks) |
| Changes in signal-averaged ECG (SA-ECG) | Measured by quantifying late potentials after depolarization of the ventricles | Baseline and after ended intervention period (12 weeks) |
| D000075224 |
| Cardiac Conduction System Disease |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D009142 |
| Musculoskeletal Physiological Phenomena |
| D055687 | Musculoskeletal and Neural Physiological Phenomena |